Diligence memo · auto-generated · as of July 3, 2026
Elevation Oncology, Inc.
Elevation Oncology, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Elevation Oncology, Inc. operates in Pharma, based in NEW YORK.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Elevation Oncology, Inc. has raised $70M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $65M on 2020-11-10.
Most recent recorded round closed around 2020-11-10.
Valuation (modeled)modeled
Provath models Elevation Oncology, Inc. at approximately $2.0B (range $211M–$5.0B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.00× the median modeled value of Series C Pharma companies in 2019–2021 (7 peers) — value vs value, same stage and era. Within the normal band (100% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 16 months.
Last raise 5.6 yr ago; this sector typically re-raises about every 16 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 11.9× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 88% of Pharma peers (310 compared).
Modeled value ranks above 94% of those peers.
Closest niche peers: Ansun Biopharma, Inc., Integrated Oncology Network Holdco, LLC, Tallac Therapeutics, Inc., CERo Therapeutics, Inc., Levo Therapeutics, Inc..
Peoplefiled
8 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.